Liquid Biopsy: It's the Bloody Truth!
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33795259.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0531 and PMC identifier 8172457.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Liquid biopsy is a promising clinical tool that can provide critical information for prognostication and which may inform treatment decisions in men with metastatic castration-resistant prostate cancer. Here we discuss the Foundation Medicine plasma cell-free circulating tumor DNA assay, its pros and cons, and potential clinical utility.<i>See related article by Tukachinsky et al., p. 3094</i>.
Medical subject headings
- Circulating Tumor DNA
- Prostatic Neoplasms